Prospective Observational Study on Hematological Evaluation of Methotrexate and Dapsone in a Tertiary Care Hospital

Background: Methotrexate and Dapsone are widely used in the treatment of autoimmune and dermatological disorders. Both drugs are associated with potential haematological adverse effects, necessitating regular monitoring to ensure patient safety. However, real-world data on their haematological impact in Indian clinical settings remains limited. Objective: To evaluate and compare the haematological profiles of patients receiving Methotrexate and Dapsone in a tertiary care hospital, and to identify the incidence and nature of associated haematological abnormalities. Methods: This prospective observational study was conducted over a [insert duration] period in the Department of Dermatology/Medicine at Saisudha Hospital. Patients prescribed Methotrexate or Dapsone for various clinical indications were enrolled following informed consent. Baseline and follow-up haematological parameters, including hemoglobin, total and differential leukocyte counts, platelet counts, and other relevant indices, were recorded and analyzed. Results: A total of 50 patients were included, with 23 receiving Methotrexate 27 receiving Dapsone. Haematological abnormalities such as anemia, leukopenia, and thrombocytopenia were observed in [insert percentage] of Methotrexate users and [insert percentage] of Dapsone users. The onset, severity, and reversibility of these abnormalities varied across individuals and were influenced by dose, duration, and comorbid conditions. Conclusion: Both Methotrexate and Dapsone are associated with significant haematological changes that warrant routine monitoring. Early detection and timely intervention can prevent serious complications. This study highlights the importance of individualized patient evaluation and contributes to the optimization of drug safety in clinical practice.